ArriVent’s AVBP Plunges 60% After Lung Cancer Trial Misses Primary Endpoint
ArriVent shares plunged 60% after its lung-cancer trial missed the primary endpoint, despite dose-dependent response rates favoring the high…
BridgeBio’s $BBIO Gains FDA Priority Review for Oral Infigratinib in Children With Achondroplasia
BridgeBio’s NDA for oral infigratinib received FDA acceptance and Priority Review, creating a closely watched regulatory catalyst for $BBIO.
Vaxcyte Hits 52-Week High as Phase 3 Data Boosts VAX-31 Prospects
Vaxcyte reached a new 52-week high after positive topline Phase 3 OPUS-1 results strengthened the case for its VAX-31 vaccine.
Alvotech Shares Jump 13.5% After FDA Clears AVT02 Manufacturing Changes
Alvotech’s $ALVO shares jumped 13.5% after FDA approval of AVT02 manufacturing changes, sharpening the focus on supply and commercial scale-…
Harrow Expands Ophthalmology Franchise With Completed TYRVAYA Acquisition
Harrow completed its TYRVAYA acquisition, adding the first and only FDA-approved nasal spray for dry eye disease to its ocular surface portf…
GE HealthCare’s $945 Million Sofie Deal Signals Broader Radiopharmaceutical Push
GE HealthCare’s $945 million Sofie Biosciences acquisition could deepen its precision-imaging strategy while putting integration costs under…
Qiagen Shares Gain as Strategic-Buyer Talks Raise M&A Speculation
Qiagen shares gained after a report said talks with a strategic buyer had advanced, reviving questions about consolidation in diagnostics.
Pancreatic Cancer Drug Approval Could Lift Oncology Biotech Sentiment
An FDA approval for metastatic pancreatic cancer may improve sentiment across oncology biotech, though investors still lack company-specific…
AbbVie’s JUVMO Approval Opens New Parkinson’s Growth Opportunity for Investors
AbbVie’s FDA approval of JUVMO may expand its neurology pipeline and offer a potential diversification catalyst beyond immunology.
Spyre Therapeutics Insiders Sell More Than $3.6 Million in SYRE Stock Despite Bullish Analyst Coverage
Spyre insiders sold more than $3.6 million in SYRE stock as JPMorgan and Baird maintained bullish views, sharpening the debate over volatili…
MRNA’s Nasdaq-100 Inclusion Draws Retail Attention to SLS and IBRX
Moderna’s Nasdaq-100 inclusion may increase index-related attention, while retail traders compare smaller biotech names SLS and IBRX.
AbbVie Wins FDA Approval for JUVMO Parkinson’s Therapy: What ABBV Investors Should Watch
AbbVie’s FDA approval of JUVMO adds a Parkinson’s therapy to its neuroscience portfolio, but commercial execution remains the next test.











